HopeStage
Back to all studies
TerminatedNCT05051449

Ketamine for OUD and Comorbid Depression (OUDCD)

Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
BaltimoreSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: April 4, 2022
Recruitment status
Terminated
Enrollment listed in the registry
5
Sponsor
University of Maryland, Baltimore
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05051449
Official title
Show the full official title

Increasing Retention in Methadone Maintenance Treatment: Feasibility and Preliminary Efficacy of Ketamine for the Treatment of Patients With OUD and Comorbid Depression (OUDCD)

Recruitment & locations

Terminated

Baltimore

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Maryland, Baltimore, a university.

Does this study involve medication?

Yes. The study involves medication, including Ketamine Hydrochloride.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies